EXMceuticals Inc. engages in the sustainable cultivation, processing, and export of non-psychotropic and psychotropic pharmaceutical-grade cannabinoid ingredients from Africa.
The last earnings update was 115 days ago.
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
EXMceuticals. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
EXMceuticals's earnings available for a low price, and how does
this compare to other companies in the same industry?
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as EXMceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare EXMceuticals's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare EXMceuticals's earnings growth to the Canada market average as no estimate data is available.
Unable to compare EXMceuticals's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if EXMceuticals is high growth as no earnings estimate data is available.
Unable to determine if EXMceuticals is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
EXMceuticals's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
Mr. Michel Passebon serves as Chief Executive Officer and Director of EXMceuticals Inc. Mr. Passebon is the Chairman of the Board of EXMfarming. He is a senior executive and engineer with over 35 years of experience in the construction, management and leadership of projects at an international level. His extensive and varied experience includes infrastructure, industry, environment, services and logistics. Mr. Passebon worked on long-term assignments in a dozen countries, giving him vast international experience and fuelling his keen knowledge of people and culture. He was the lead project manager in the development, implementation and operation of a large-scale stevia farming and a sweeteners extraction venture with offices in France and farm operations in Angola and Rwanda.
Insufficient data for Michel to compare compensation growth.
Insufficient data for Michel to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure
Average tenure of the
management team in years:
The average tenure for the EXMceuticals management team is less than 2 years, this suggests a new team.
CEO & Director
Interim Chief Financial Officer
Chief Operating Officer
Chief Administrative Officer
Chief Strategy Officer
Senior Scientific Advisor & CEO -Portugal
Board of Directors
CEO & Director
Who owns this company?
Recent Insider Trading
No 3 month open market individual insider trading information.
EXMceuticals Inc. engages in the sustainable cultivation, processing, and export of non-psychotropic and psychotropic pharmaceutical-grade cannabinoid ingredients from Africa. If focuses on offering Cannabidiol (CBD), a non-psychoactive cannabinoid that has been proven effective against acne, anxiety, depression, epilepsy, and degenerative diseases, such as Parkinson’s; and Tetrahydrocannabinol (THC), a psychoactive cannabinoid ingredient that has been proven effective in the fields of pain management, appetite control, anxiety, and managing side effects of chemotherapy. The company was founded in 2017 and is headquartered in Vancouver, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.